Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03115983
Previous Study | Return to List | Next Study

LimiFlex Clinical Trial for the Treatment of Degenerative Spondylolisthesis With Spinal Stenosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03115983
Recruitment Status : Active, not recruiting
First Posted : April 14, 2017
Last Update Posted : August 7, 2020
Sponsor:
Collaborators:
Morley Research Consortium
Biomedical Statistical Consulting
Medical Metrics Diagnostics, Inc
Information provided by (Responsible Party):
Empirical Spine, Inc.

Brief Summary:
The LimiFlex™ Clinical Trial is a prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of decompression and stabilization with the Empirical Spine LimiFlex™ Paraspinous Tension Band compared to decompression and transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) for the treatment of lumbar degenerative spondylolisthesis (Grade I per Meyerding classification) with spinal stenosis. Clinical trial sites will enroll solely LimiFlex subjects or solely TLIF/PLF subjects.

Condition or disease Intervention/treatment Phase
Degenerative Spondylolisthesis Lumbar Spinal Stenosis Device: LimiFlex Device: Fusion Instrumentation Procedure: Decompression Procedure: Fusion Not Applicable

Detailed Description:
The LimiFlex™ Paraspinous Tension Band is a new stabilization option for patients being treated with surgical decompression for degenerative spondylolisthesis. The LimiFlex does not require pedicle screws to anchor to the spine; instead, two dynamic rods are attached to pedicle-sparing straps which encircle adjacent spinous processes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 400 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a multi-center, prospective, concurrently controlled, non-blinded study. Balance between groups will be achieved through sub classification using propensity scores. Prospective patient sample supplemented with retrospective and/or historical control subjects.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Concurrently Controlled Study of the LimiFlex™ Paraspinous Tension Band in the Treatment of Lumbar Degenerative Spondylolisthesis With Spinal Stenosis
Actual Study Start Date : July 17, 2017
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Spinal Stenosis

Arm Intervention/treatment
Experimental: LimiFlex
Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
Device: LimiFlex
LimiFlex implantation at a single level after surgical decompression.
Other Name: LimiFlex Paraspinous Tension Band

Procedure: Decompression
Surgical decompression at one or two contiguous levels for L1 to S1.

Active Comparator: Fusion
Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
Device: Fusion Instrumentation
Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).

Procedure: Decompression
Surgical decompression at one or two contiguous levels for L1 to S1.

Procedure: Fusion
Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.




Primary Outcome Measures :
  1. Composite Clinical Success [ Time Frame: 24 Months ]

    Individual success for patients in the investigational LimiFlex or control fusion arm is assessed with Composite Clinical Success (CCS) criteria. To be considered a success, a subject must demonstrate all of the following:

    • 15 point improvement in Oswestry Disability Index (100 point scale)
    • Absence of a new or worsening, persistent neurological deficit
    • Absence of additional surgical intervention
    • Absence of device integrity failures


Secondary Outcome Measures :
  1. Oswestry Disability Index (ODI) [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Oswestry Disability Index (ODI)

  2. Neurological Status [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Neurological Status

  3. Additional surgical interventions [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Additional surgical interventions

  4. Absence of device integrity failures defined as device breakage, device separation or disassembly, or device dislocation [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Absence of device integrity failures defined as device breakage, device separation or disassembly, or device dislocation

  5. Estimated blood loss [ Time Frame: Procedure ]
    estimated blood loss and units of blood transfused

  6. Length of procedure [ Time Frame: Procedure ]
    Length of procedure (skin to skin)

  7. Hospital stay [ Time Frame: Immediately upon discharge ]
    Hospital stay

  8. Return to normal activities of daily living [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Length of time for subject to return to his/her normal activities of daily living.

  9. Work status [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Work status and days to return to work (as appropriate)

  10. Pain medication including narcotics usage [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Medication use for pain, including narcotic, usage

  11. Visual analog scale (VAS) leg pain [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Leg pain as measured on a Visual Analog Scale (VAS)

  12. Visual analog scale (VAS) back pain [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Back pain as measured on a Visual Analog Scale (VAS)

  13. Zurich claudication questionnaire (ZCQ) [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Zurich claudication questionnaire

  14. SF-12 Quality of Life survey [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    SF-12 Health Survey

  15. Patient satisfaction [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Patient satisfaction questionnaire

  16. Radiographic fusion status [ Time Frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo ]
    Radiographic fusion status



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (patients must meet ALL of the following criteria to be eligible for participation in the study):

  1. Lumbar degenerative spondylolisthesis (Grade I per Meyerding classification), at one level from L1 to S1, with radiographic confirmation using X-ray;

    a. Grade I spondylolisthesis per Meyerding classification includes up to 25% anterior translation of a vertebra relative to the superior endplate of the subjacent vertebra at the index level. A patient is considered to have spondylolisthesis with a minimum 10% anterolisthesis at the affected level in a lateral x-ray image.

  2. Lumbar spinal stenosis, at the level diagnosed with degenerative spondylolisthesis, and confirmed radiographically using CT or MRI;

    a. At the index level, lumbar spinal stenosis is at least moderate lumbar canal stenosis, defined as more than 25% reduction of the cross-sectional area compared with the next adjacent normal level, with nerve root crowding compared with the normal level, as determined by the investigator on CT Scan or MRI.

  3. Neurogenic claudication or radiculopathy symptoms including leg pain, muscle weakness, and/or sensation abnormality, with or without back pain as evidenced by patient history;
  4. Persistent symptoms despite at least 6 months of conservative treatment that may include but is not limited to physical therapy, medications, and/or epidural injections;
  5. A pre-operative Visual Analog Scale (VAS) leg pain score of ≥50 on a 100 mm scale;
  6. A pre-operative Oswestry Disability Index (ODI) score ≥35 points on a 100-point scale;
  7. Candidate for surgical decompression and stabilization at only one level between L1-S1;
  8. Posterior element anatomy is appropriate for interspinous fixation including prediction of presence of spinous processes of segment to be instrumented following decompression (investigational AND control groups) and a prediction of >50% of facet joints present following decompression (investigational group only);
  9. ≥25-80 years of age and skeletally mature;
  10. Patient has the necessary mental capacity to participate and is willing and able to participate in the study for the duration of the study follow-up and is able to comply with study requirements; and
  11. Patient is willing to provide Informed Consent for study participation.

Exclusion Criteria:

  1. A primary and predominate diagnosis of discogenic back pain;
  2. A primary and predominate diagnosis of facet-mediated back pain;
  3. Back or non-radicular leg pain of unknown etiology;
  4. Significant peripheral vascular disease causing vascular claudication;
  5. Significant peripheral neuropathy caused by conditions other than spinal stenosis;
  6. History of fixed or permanent neurological deficit related to spinal cord injury;
  7. History of any previous surgery* at any level in the lumbosacral spine except for a discectomy or decompression;
  8. History of any previous surgery* at the level planned for treatment;

    • previous surgery includes spinal stimulator placement but does NOT include epidural injections
  9. Isthmic spondylolisthesis or spondylolysis (pars fracture) at any level in the lumbar spine;
  10. Clinically significant compromise of vertebrae at L1 to S1 levels due to osteoporotic vertebral compression fracture or any traumatic, neoplastic, metabolic or infectious pathology or congenital abnormality;
  11. Spinous process fracture(s) or other posterior element fracture(s) of the segment to be instrumented that would preclude secure fixation of the LimiFlex Device to the spinous process;
  12. Spinous process insufficiency or deformity that would preclude secure fixation of the LimiFlex Device to the spinous process including spinous process length <10 mm from lamina to dorsal tip or other significant deformity due to trauma, or congenital abnormality such as spina bifida occulta at the planned instrumented level that would preclude secure fixation of the LimiFlex Device to the spinous process;
  13. The estimated distance between the LimiFlex Device strap attachment points (midpoint of the cranial edge of the cranial spinous process and the midpoint of the caudal edge of the caudal spinous process) is <30mm on pre-operative lateral standing radiographs at the segment to be instrumented;
  14. Degenerative lumbar scoliosis with a Cobb angle >10° at the affected motion segment;
  15. Symptomatic lumbar stenosis that is not amenable to a direct decompression
  16. Anklyosed motion segment at the target operative level
  17. Severe osteoporosis, defined as history of fragility fracture and DXA T-score <-2.5 or QCT T-score < -2.5. History of a fragility fracture requires that a DXA scan or QCT scan is completed;
  18. Planned hip or knee replacement surgery;
  19. Documented allergy to titanium or polyethylene;
  20. Active local or systemic infection;
  21. Receiving immunosuppressive or long-term steroid therapy;
  22. Known history of bone metabolic disorder, including Paget's disease, hyperparathyroidism, renal osteodystrophy, and osteomalacia;
  23. Disease or condition that would preclude accurate clinical evaluation of the safety and effectiveness of the study treatment or any significant medical conditions which would place the patient at excessive risk for surgery, such as:

    1. severe rheumatoid arthritis or other severe autoimmune disease
    2. active hepatitis (viral or serum) or HIV positive
    3. unstable cardiac disease
    4. uncontrolled diabetes
    5. renal failure
    6. severe muscular, neural or vascular diseases that endanger the spinal column
    7. cauda equina syndrome
    8. severe neurologic disorders including paralysis
  24. Morbid obesity defined as BMI >40;
  25. History of malignancy within the last five years;
  26. Women who are pregnant or are interested in becoming pregnant within the study period;
  27. Currently seeking or receiving worker's compensation for back pain or spinal condition;
  28. Currently involved in spinal litigation that potentially is associated with secondary financial gain;
  29. Current involvement in a study of another investigational product for similar purpose;
  30. Demonstrates three or more Waddell's Signs of Inorganic Behavior;
  31. Active treatment of a major psychiatric condition, such as major depression, anxiety disorder, bipolar disorder, schizophrenia, personality disorder, that could prevent accurate completion of self reporting assessment scales;
  32. Current history (within 12 months) of substance abuse, including alcohol abuse; or
  33. A prisoner.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03115983


Locations
Show Show 27 study locations
Sponsors and Collaborators
Empirical Spine, Inc.
Morley Research Consortium
Biomedical Statistical Consulting
Medical Metrics Diagnostics, Inc
Investigators
Layout table for investigator information
Principal Investigator: Rick Sasso, MD Indiana Spine Group
Principal Investigator: William C Welch, MD Pennsylvania Hospital Neurosurgery
Layout table for additonal information
Responsible Party: Empirical Spine, Inc.
ClinicalTrials.gov Identifier: NCT03115983    
Other Study ID Numbers: LSS17001
First Posted: April 14, 2017    Key Record Dates
Last Update Posted: August 7, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Stenosis
Spondylolisthesis
Constriction, Pathologic
Pathological Conditions, Anatomical
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Spondylolysis
Spondylosis